AT Bancorp bought a new stake in Laboratory Corp. of America Holdings (NYSE:LH) during the third quarter, Holdings Channel reports. The fund bought 9,463 shares of the company’s stock, valued at approximately $1,302,000.

Other hedge funds have also added to or reduced their stakes in the company. Boston Partners boosted its position in Laboratory Corp. of America Holdings by 78.5% in the second quarter. Boston Partners now owns 3,555,298 shares of the company’s stock valued at $463,149,000 after buying an additional 1,563,105 shares in the last quarter. Vanguard Group Inc. boosted its position in Laboratory Corp. of America Holdings by 5.2% in the second quarter. Vanguard Group Inc. now owns 9,406,648 shares of the company’s stock valued at $1,225,404,000 after buying an additional 463,343 shares in the last quarter. Silvercrest Asset Management Group LLC purchased a new position in Laboratory Corp. of America Holdings during the second quarter valued at $51,661,000. Bank of Montreal Can purchased a new position in Laboratory Corp. of America Holdings during the second quarter valued at $49,845,000. Finally, Bessemer Group Inc. boosted its position in Laboratory Corp. of America Holdings by 58.9% in the second quarter. Bessemer Group Inc. now owns 850,573 shares of the company’s stock valued at $110,804,000 after buying an additional 315,250 shares in the last quarter. Hedge funds and other institutional investors own 91.24% of the company’s stock.

Institutional Ownership by Quarter for Laboratory Corp. of America Holdings (NYSE:LH)

Shares of Laboratory Corp. of America Holdings (NYSE:LH) traded up 1.60% on Tuesday, hitting $127.72. The stock had a trading volume of 459,017 shares. The stock has a 50 day moving average of $129.54 and a 200 day moving average of $133.00. Laboratory Corp. of America Holdings has a 12-month low of $97.79 and a 12-month high of $141.32. The firm has a market cap of $13.16 billion, a price-to-earnings ratio of 20.25 and a beta of 0.96.

Laboratory Corp. of America Holdings (NYSE:LH) last posted its quarterly earnings results on Wednesday, October 26th. The company reported $2.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.29 by $0.04. The company earned $2.40 billion during the quarter, compared to analysts’ expectations of $2.38 billion. Laboratory Corp. of America Holdings had a net margin of 6.85% and a return on equity of 16.97%. Laboratory Corp. of America Holdings’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $2.07 earnings per share. Equities analysts predict that Laboratory Corp. of America Holdings will post $8.78 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Financial Market News and is owned by of Financial Market News. If you are reading this piece on another site, it was illegally stolen and republished in violation of US & international copyright legislation. The legal version of this piece can be read at http://www.financial-market-news.com/at-bancorp-buys-new-stake-in-laboratory-corp-of-america-holdings-lh/1209513/.

Several equities analysts have weighed in on the company. KeyCorp raised their price target on Laboratory Corp. of America Holdings from $143.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, August 16th. Gabelli started coverage on Laboratory Corp. of America Holdings in a report on Tuesday, October 25th. They set a “buy” rating and a $180.00 price target for the company. Zacks Investment Research cut Laboratory Corp. of America Holdings from a “buy” rating to a “hold” rating in a report on Tuesday, October 25th. Citigroup Inc. started coverage on Laboratory Corp. of America Holdings in a report on Friday, September 9th. They issued a “neutral” rating and a $156.00 target price for the company. They noted that the move was a valuation call. Finally, Barclays PLC set a $155.00 target price on Laboratory Corp. of America Holdings and gave the stock a “buy” rating in a report on Monday, August 29th. Eight equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $143.13.

Laboratory Corp. of America Holdings Company Profile

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

5 Day Chart for NYSE:LH

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Receive News & Ratings for Laboratory Corp. of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.